GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma

Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients wi...

Full description

Bibliographic Details
Main Authors:	Alphonse, M.P (Author), Bordeaux, Z.A (Author), Braun, G. (Author), Choi, J. (Author), Davis, C. (Author), Kwatra, M.M (Author), Kwatra, S.G (Author), McKeel, J. (Author), Miller, M.N (Author), Nanni, C. (Author), Sutaria, N. (Author), West, C.E (Author)
Format:	Article
Language:	English
Published:	MDPI 2022
Subjects:	EGFR EGFRvIII glioblastoma glioblastoma stem cells super-enhancer
Online Access:	View Fulltext in Publisher

by Alphonse, M.P, Bordeaux, Z.A, Braun, G., Choi, J., Davis, C., Kwatra, M.M, Kwatra, S.G, McKeel, J., Miller, M.N, Nanni, C., Sutaria, N., West, C.E
Published 2022

View Fulltext in Publisher

Article

GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma

Similar Items